2026 H1 - tulosraportti
20 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 554 | - | - | ||
| 4 | - | - | ||
| 1 826 | - | - | ||
| 800 | - | - | ||
| 139 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sitten · MuokattuA lot of talk about shorting here, even though it's relatively little for TRMED. But if you want to follow a bit extra, I've made my own solution. Only for private use really, but happy to share. A kind of short-radar for Oslo Børs. The data comes from Finanstilsynet's short register and shows Norwegian stocks with positions of 0.5 percent or more. The site automatically fetches fresh numbers. You can see changes for the last day, week, month, and three months, and click on each stock to see which players have shorted and how it has developed. You can mark your own favorites. They are only stored in your own browser, so no one else sees them. Thor Medical comes as a favorite for everyone, naturally enough: https://shortaksjer.netlify.app Input to make it better is welcome, but this is on a hobby basis. Without commercial interests. And no, adding prices is not relevant, this is purely short-info.
·8 t sittenNow people have probably had enough opportunities to shop at the issue price of 4.80. Perhaps issue a press release about dropping the repair issue?
Got AI to create a summary for Circio and what's happening around the share issue, with a bit of humor. It fits well here too; "Guys," whispered Wiklund. "We're doing a share issue. You can buy at 11.80 kroner – or well below if the market panics."The guys cheered and adjusted their imaginary broker vests. This was cheaper than a lukewarm hot dog at the gas station.When the stock exchange announcement hit the market, the trading robots went haywire. The price chart plunged, redder than a sunburned tourist in the Mediterranean. On the internet, small investors raged and called for the Financial Supervisory Authority, while selling in panic.In the Circio camp, the guys hammered the buy button. 11.50... 11.20... Shares poured into their accounts.Wiklund took a calm sip of coffee and smiled at the screens: "The market is always right. But today, they just really, really wanted to give us a discount."
·1 päivä sittenThe short position in Thor Medical has increased noticeably recently. Two Sigma has built up from 0.65 % on September 4th to 1.03 % publicly registered short. Of course, this does not mean that all decline is due to short or that manipulation is necessarily taking place. But the increase is large enough to be relevant. At the same time, these shares must be bought back at some point – and with strong news, covering can provide extra upward momentum.It could be entertaining for those interested to follow along here when they have to cover 3.716.342 shares.
·1 päivä sitten · MuokattuCEO Thijs Spoor is participating today in the Morgan Stanley Global Healthcare Conference, where he will take part in an informal conversation at 11:30 AM ET (5:30 PM Norwegian time). The conversation will revolve around the path to Phase 3 for VMT-α-NET, upcoming clinical milestones in the development portfolio, and production readiness to support later-stage development. It's worth following this – even if they are not yet partners with Thor Medical, they could easily become so. Pb212! https://www.linkedin.com/posts/perspective-therapeutics_ceo-thijs-spoor-joins-the-morgan-stanley-activity-7505959122115129364-OXhP?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WY
Worth keeping an eye on, but it's important to keep your wits about you. Perspective Therapeutics is not a partner with Thor Medical today; I have followed them for a long time and am an investor there myself. They have their own agreement with the American DOE for thorium 228 and their own generator for Pb 212. What they are talking about at Morgan Stanley is the path towards phase 3 for VMT-α-NET and that they must have production capacity that can handle later phases. What still matters for TRMED, however, is the market itself. VMT-α-NET is one of the most visible Pb 212 programs out there. When such companies move towards phase 3, the need for stable, industrial access to isotopes increases. Then it becomes more valuable that someone actually has a factory in operation and can deliver in volume. And that ties right into what Thor is doing now. They raised 300 million, among other things, to enter the USA with downstream production of Pb 212, closer to the customers. Not a new AlphaOne overnight, but capacity where the market actually is. So no, this is not an agreement today. But the direction is the same. CATX shows where the market is going, Thor is building to meet it.🫡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
20 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sitten · MuokattuA lot of talk about shorting here, even though it's relatively little for TRMED. But if you want to follow a bit extra, I've made my own solution. Only for private use really, but happy to share. A kind of short-radar for Oslo Børs. The data comes from Finanstilsynet's short register and shows Norwegian stocks with positions of 0.5 percent or more. The site automatically fetches fresh numbers. You can see changes for the last day, week, month, and three months, and click on each stock to see which players have shorted and how it has developed. You can mark your own favorites. They are only stored in your own browser, so no one else sees them. Thor Medical comes as a favorite for everyone, naturally enough: https://shortaksjer.netlify.app Input to make it better is welcome, but this is on a hobby basis. Without commercial interests. And no, adding prices is not relevant, this is purely short-info.
- ·8 t sittenNow people have probably had enough opportunities to shop at the issue price of 4.80. Perhaps issue a press release about dropping the repair issue?Got AI to create a summary for Circio and what's happening around the share issue, with a bit of humor. It fits well here too; "Guys," whispered Wiklund. "We're doing a share issue. You can buy at 11.80 kroner – or well below if the market panics."The guys cheered and adjusted their imaginary broker vests. This was cheaper than a lukewarm hot dog at the gas station.When the stock exchange announcement hit the market, the trading robots went haywire. The price chart plunged, redder than a sunburned tourist in the Mediterranean. On the internet, small investors raged and called for the Financial Supervisory Authority, while selling in panic.In the Circio camp, the guys hammered the buy button. 11.50... 11.20... Shares poured into their accounts.Wiklund took a calm sip of coffee and smiled at the screens: "The market is always right. But today, they just really, really wanted to give us a discount."
- ·1 päivä sittenThe short position in Thor Medical has increased noticeably recently. Two Sigma has built up from 0.65 % on September 4th to 1.03 % publicly registered short. Of course, this does not mean that all decline is due to short or that manipulation is necessarily taking place. But the increase is large enough to be relevant. At the same time, these shares must be bought back at some point – and with strong news, covering can provide extra upward momentum.It could be entertaining for those interested to follow along here when they have to cover 3.716.342 shares.
- ·1 päivä sitten · MuokattuCEO Thijs Spoor is participating today in the Morgan Stanley Global Healthcare Conference, where he will take part in an informal conversation at 11:30 AM ET (5:30 PM Norwegian time). The conversation will revolve around the path to Phase 3 for VMT-α-NET, upcoming clinical milestones in the development portfolio, and production readiness to support later-stage development. It's worth following this – even if they are not yet partners with Thor Medical, they could easily become so. Pb212! https://www.linkedin.com/posts/perspective-therapeutics_ceo-thijs-spoor-joins-the-morgan-stanley-activity-7505959122115129364-OXhP?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WYWorth keeping an eye on, but it's important to keep your wits about you. Perspective Therapeutics is not a partner with Thor Medical today; I have followed them for a long time and am an investor there myself. They have their own agreement with the American DOE for thorium 228 and their own generator for Pb 212. What they are talking about at Morgan Stanley is the path towards phase 3 for VMT-α-NET and that they must have production capacity that can handle later phases. What still matters for TRMED, however, is the market itself. VMT-α-NET is one of the most visible Pb 212 programs out there. When such companies move towards phase 3, the need for stable, industrial access to isotopes increases. Then it becomes more valuable that someone actually has a factory in operation and can deliver in volume. And that ties right into what Thor is doing now. They raised 300 million, among other things, to enter the USA with downstream production of Pb 212, closer to the customers. Not a new AlphaOne overnight, but capacity where the market actually is. So no, this is not an agreement today. But the direction is the same. CATX shows where the market is going, Thor is building to meet it.🫡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 554 | - | - | ||
| 4 | - | - | ||
| 1 826 | - | - | ||
| 800 | - | - | ||
| 139 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
20 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sitten · MuokattuA lot of talk about shorting here, even though it's relatively little for TRMED. But if you want to follow a bit extra, I've made my own solution. Only for private use really, but happy to share. A kind of short-radar for Oslo Børs. The data comes from Finanstilsynet's short register and shows Norwegian stocks with positions of 0.5 percent or more. The site automatically fetches fresh numbers. You can see changes for the last day, week, month, and three months, and click on each stock to see which players have shorted and how it has developed. You can mark your own favorites. They are only stored in your own browser, so no one else sees them. Thor Medical comes as a favorite for everyone, naturally enough: https://shortaksjer.netlify.app Input to make it better is welcome, but this is on a hobby basis. Without commercial interests. And no, adding prices is not relevant, this is purely short-info.
- ·8 t sittenNow people have probably had enough opportunities to shop at the issue price of 4.80. Perhaps issue a press release about dropping the repair issue?Got AI to create a summary for Circio and what's happening around the share issue, with a bit of humor. It fits well here too; "Guys," whispered Wiklund. "We're doing a share issue. You can buy at 11.80 kroner – or well below if the market panics."The guys cheered and adjusted their imaginary broker vests. This was cheaper than a lukewarm hot dog at the gas station.When the stock exchange announcement hit the market, the trading robots went haywire. The price chart plunged, redder than a sunburned tourist in the Mediterranean. On the internet, small investors raged and called for the Financial Supervisory Authority, while selling in panic.In the Circio camp, the guys hammered the buy button. 11.50... 11.20... Shares poured into their accounts.Wiklund took a calm sip of coffee and smiled at the screens: "The market is always right. But today, they just really, really wanted to give us a discount."
- ·1 päivä sittenThe short position in Thor Medical has increased noticeably recently. Two Sigma has built up from 0.65 % on September 4th to 1.03 % publicly registered short. Of course, this does not mean that all decline is due to short or that manipulation is necessarily taking place. But the increase is large enough to be relevant. At the same time, these shares must be bought back at some point – and with strong news, covering can provide extra upward momentum.It could be entertaining for those interested to follow along here when they have to cover 3.716.342 shares.
- ·1 päivä sitten · MuokattuCEO Thijs Spoor is participating today in the Morgan Stanley Global Healthcare Conference, where he will take part in an informal conversation at 11:30 AM ET (5:30 PM Norwegian time). The conversation will revolve around the path to Phase 3 for VMT-α-NET, upcoming clinical milestones in the development portfolio, and production readiness to support later-stage development. It's worth following this – even if they are not yet partners with Thor Medical, they could easily become so. Pb212! https://www.linkedin.com/posts/perspective-therapeutics_ceo-thijs-spoor-joins-the-morgan-stanley-activity-7505959122115129364-OXhP?utm_source=share&utm_medium=member_ios&rcm=ACoAADUVyGgBbKFcdpxXInSkiOE2XLD9nnPl2WYWorth keeping an eye on, but it's important to keep your wits about you. Perspective Therapeutics is not a partner with Thor Medical today; I have followed them for a long time and am an investor there myself. They have their own agreement with the American DOE for thorium 228 and their own generator for Pb 212. What they are talking about at Morgan Stanley is the path towards phase 3 for VMT-α-NET and that they must have production capacity that can handle later phases. What still matters for TRMED, however, is the market itself. VMT-α-NET is one of the most visible Pb 212 programs out there. When such companies move towards phase 3, the need for stable, industrial access to isotopes increases. Then it becomes more valuable that someone actually has a factory in operation and can deliver in volume. And that ties right into what Thor is doing now. They raised 300 million, among other things, to enter the USA with downstream production of Pb 212, closer to the customers. Not a new AlphaOne overnight, but capacity where the market actually is. So no, this is not an agreement today. But the direction is the same. CATX shows where the market is going, Thor is building to meet it.🫡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 554 | - | - | ||
| 4 | - | - | ||
| 1 826 | - | - | ||
| 800 | - | - | ||
| 139 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt